Crcm LP Has $1.02 Million Stock Holdings in Burning Rock Biotech Limited Sponsored ADR $BNR

Key Points

• Crcm LP has reduced its stake in Burning Rock Biotech by 30.6%, selling 99,679 shares in the first quarter, leaving it with 226,290 shares.
• Citadel Advisors LLC has acquired a new stake in Burning Rock Biotech, indicating ongoing interest from institutional investors, with about 30.03% of the stock owned by such entities.
• Shares of Burning Rock Biotech traded down 7.9% recently, currently priced at approximately $8.60, with a market capitalization of $92.54 million.

Crcm LP trimmed its position in Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR - Free Report) by 30.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 226,290 shares of the company's stock after selling 99,679 shares during the period. Burning Rock Biotech makes up approximately 0.4% of Crcm LP's holdings, making the stock its 5th biggest holding. Crcm LP owned 2.21% of Burning Rock Biotech worth $1,018,000 at the end of the most recent reporting period.

Separately, Citadel Advisors LLC acquired a new stake in shares of Burning Rock Biotech in the 4th quarter valued at approximately $83,000. 30.03% of the stock is currently owned by hedge funds and other institutional investors.

Burning Rock Biotech Trading Up 3.2%

Shares of NASDAQ:BNR traded up $0.26 during mid-day trading on Friday, reaching $8.55. The stock had a trading volume of 30,589 shares, compared to its average volume of 44,375. The firm has a market cap of $92.04 million, a PE ratio of -4.53 and a beta of 0.83. The firm has a 50 day simple moving average of $5.97 and a two-hundred day simple moving average of $4.74. Burning Rock Biotech Limited Sponsored ADR has a twelve month low of $2.18 and a twelve month high of $11.12.

Burning Rock Biotech (NASDAQ:BNR - Get Free Report) last announced its quarterly earnings results on Friday, June 6th. The company reported ($0.17) earnings per share for the quarter. The firm had revenue of $18.34 million during the quarter. Burning Rock Biotech had a negative net margin of 45.41% and a negative return on equity of 38.33%.

About Burning Rock Biotech

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.